In the next decade, innovative drugs will become an important and flexible main line of domestic pharmaceutical investment

[pharmaceutical network market analysis] in recent years, the pharmaceutical industry has experienced changes in the pattern brought about by medical reform policies, such as consistency evaluation, two vote system, and "4 + 7" volume procurement In the eyes of some pharmaceutical people, the pharmaceutical circle is shrouded in dark clouds, but more and more pharmaceutical people are beginning to return to rationality and take the road of innovation and development "The pharmaceutical industry is in an era of both challenges and opportunities Innovative drugs are the sustained driving force of pharmaceutical enterprises, and also the winning point for pharmaceutical enterprises to seek development breakthroughs in the new situation!" According to the analysis of the insiders, the subdivision of innovative drugs has the policy basis, technical basis, market basis, catalyst basis and so on After more than ten years of accumulation, China's innovative drug industry has a single spark, which can start a prairie fire From 2015 to 2017, there have been several representatives of independent innovative drugs in China who have successively achieved commercial success The deepening of drug administration reform has created a better regulatory environment for the subsequent approval of innovative drugs "In the next decade, innovative drugs will become an important and flexible main line of domestic pharmaceutical investment." The person stressed In recent years, China attaches great importance to pharmaceutical innovation The national innovation driven development strategy outline, the 13th five year plan for national science and technology innovation, the pharmaceutical industry development planning guide and other planning guidelines all set out the development goals of innovative drugs, and set up special projects to promote new drug research and development In addition, the preferential review, compensation and data protection policies for innovative drugs accelerate the development of new drugs Innovative drugs and innovative technologies have become the hot spots of industrial capital pursuit According to the analysis of the industry, China's innovation and development presents the following two characteristics Guided by clinical value Analysts pointed out that from the perspective of clinical needs, in the future, China's innovative drug research and development will mainly focus on the field of chronic diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, diabetes, while anti infective drugs will still maintain a certain proportion It shows the characteristics of interdisciplinary integration Analysts said that after the two life science and technology revolutions triggered by molecular biology and genomics, the third revolution will be triggered by the cross integration and convergence of life science, physical science, engineering, information science and other disciplines, and the innovation mode will present the characteristics of network and globalization Moreover, the cross integration of gene editing technology, tumor immunotherapy, big data, artificial intelligence, 3D printing technology and other fields will further promote the research and development of new drugs However, the R & D of innovative drugs is faced with the characteristics of high investment, high risk, high return, interdisciplinary and long cycle Therefore, before the R & D of innovative drugs, enterprises need to do a good job in R & D strategy positioning, market strategy positioning and marketing strategy positioning For example, for innovative drugs, the formulation of R & D strategy determines whether innovative drugs can be listed, and how to continue a series of follow-up actions after listing For the development of R & D strategy, industry insiders said that it is necessary to do a good job in the positioning of R & D strategy, such as which indication to use for an approval? Do you want to use biomarkers? Do you want to use pills or combination? What kind of union? In addition, in the process of innovative drug research and development, enterprises should clearly consider the expected efficacy and safety risks of drugs, as well as the evaluation of benefit risks With the accelerated implementation of consistency evaluation and "4 + 7" volume procurement, competition in the pharmaceutical industry has intensified, and innovative drugs may become a "prying point" for pharmaceutical companies to capture market share It is understood that innovative drugs have become a hot spot in the pursuit of industrial capital For this reason, some enterprises began to make large amount of financing to provide capital support for new drug research and development In addition, the return of a large number of turtle talents in recent years has also injected talent power into the research and development of innovative drugs in China Under the promotion of policies, capital, talents and other factors, China's innovative drug research and development ushered in a good opportunity for development According to the industry, those pharmaceutical enterprises with outstanding R & D strength and strong ability of new drug creation will stand out, and their R & D strategy and market strategy will usher in a big transformation.